Results 111 to 120 of about 24,684 (197)
Characteristics of eyes with secondary loss of visual acuity receiving variable dosing ranibizumab for neovascular age-related macular degeneration [PDF]
, 2018 Purpose: The aim of this work is to investigate the characteristics of eyes failing to maintain visual acuity (VA) receiving variable dosing ranibizumab for neovascular age-related macular degeneration (nAMD) after three initial loading doses. Methods: A
Ambresin, Aude +3 more
core
Traitement des membranes néovasculaires myopiques par ranibizumab : résultats à long terme. [PDF]
, 2014 Background: To report our functional results of efficacy of intravitreal ranibizumab (IVR) for submacular choroidal neovessels (CNV) in high myopia, and to compare the role of optical coherence tomography (OCT), fluorescein angiography (FA) and visual ...
LADAIQUE, M.
core
Therapeutics and Clinical Risk Management, 2012 Youxin Chen, Fei HanDepartment of Ophthalmology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, ChinaAbstract: Wet age-related macular degeneration (AMD) causes severe vision loss due
Chen Y, Han F
doaj
Kartika: Jurnal Ilmiah FarmasiAnti-vascular endothelial growth factor (VEGF) injeksi intravitreal dapat digunakan untuk terapi pasien dengan gangguan mata. Obat anti-VEGF yang digunakan di antaranya bevacizumab, ranibizumab, aflibercept, dan brolucizumab.
Nur Sidik Cahyono +1 more
doaj +1 more source
A pilot study of intralesional ranibizumab on pterygium vascularity, size and recurrence rate [PDF]
, 2015 Introduction: Pterygium is a common eye disorder in Malaysia due to the country’s location near to the equator. Recent study has found that vascular endothelial growth factor (VEGF) is present in great amount in pterygium epithelium especially in its ...
Chi, Ho Hao
core
Cost-effectiveness of age-related macular degeneration study supplements in the UK: combined trial and real-world outcomes data [PDF]
, 2018 Aims To evaluate the cost-effectiveness of Age-Related Eye Disease Study (AREDS) 1 & 2 supplements in patients with either bilateral intermediate age-related macular degeneration, AREDS category 3, or unilateral neovascular age-related macular ...
Agron, E +7 more
core
Intravitreal ranibizumab (Lucentis®) in the treatment of retinal angiomatous proliferation (RAP) [PDF]
, 2018 Background: Retinal angiomatous proliferation (RAP) is a distinct variant of neovascular age-related macular degeneration (AMD). The aim of this study is to evaluate the functional and anatomic outcome after intravitreal ranibizumab (Lucentis) treatment ...
Ambresin, Aude +5 more
core
Clinical Ophthalmology, 2013 Masahiro Miura,1,2 Takuya Iwasaki,1,2 Hiroshi Goto2 1Department of Ophthalmology, Tokyo Medical University, Ibaraki Medical Center, Ami, Ibaraki, Japan; 2Department of Ophthalmology, Tokyo Medical University, Nishi-Shinjuku, Tokyo, Japan Purpose: To ...
Miura M, Iwasaki T, Goto H
doaj
Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results [PDF]
, 2010 PURPOSE: The purpose of this study was to evaluate the safety and efficacy of intravitreal ranibizumab after 12 months in the treatment of choroidal neovascularization secondary to pathologic myopia.
Cachulo, ML +8 more
core